Therapy with sucroferric oxyhydroxide, an iron-based phosphate binder, does not spike serum iron levels or other anemia parameters in stable dialysis patients over 6 months, Georgios Lioulios, MD, of Hippokration General Hospital in Greece, reported in Blood Purification.
In a cohort of patients receiving sucroferric oxyhydroxide, no significant changes were observed in any hematologic parameter from baseline to 6 months, including hemoglobin (Hb; 11.5 to 11.4 g/dL), ferritin (475 to 473 ng/mL), and transferrin saturation (TSAT; 26.5% to 26.6%). They also required no significant changes in the administration of iron supplements or erythropoietin dose over the period.
To assess the efficacy of sucroferric oxyhydroxide for hyperphosphatemia treatment, the investigators compared the 49 patients who used sucroferric oxyhydroxide chronically (group A) with 61 patients receiving another phosphate binder or no hyperphosphatemia treatment (group B) at 6 months. Groups A and B did not differ significantly in Hb (11.4 vs 11.6 g/dL), ferritin (473 vs 436 ng/mL), and TSAT (26.6% vs 26.5%), serum phosphate (4.57 vs 4.30 mg/dL), or intact parathyroid hormone (iPTH; 286 vs 239 pg/mL). Group A had significantly but marginally higher calcium levels, however: 9.18 vs 8.90 mg/dL.
“[Sucroferric oxyhydroxide] is a safe and effective agent against hyperphosphatemia in patients with [end-stage kidney disease], not inferior to other agents. Its use does not affect iron markers or hematologic parameters and it’s not related with iron accumulation in dialysis patients,” Dr Lioulios’ team stated.
Lioulios G, Stangou M, Sarafidis PA, et al. Chronic therapy with sucroferric oxyhydroxide does not affect iron and anemia markers in dialysis patients [published online February 12, 2020]. Blood Purif. doi: 10.1159/000505432